The blood-brain barrier and cerebrovascular pathology in Alzheimer's disease

Annals of the New York Academy of Sciences

Volumn 893, Issue , 1999, Pages 113-125

  Kalaria, Raj N ^a,b  

^a NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BRAIN INJURY; BRAIN MICROCIRCULATION; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; COGNITIVE DEFECT; CONFERENCE PAPER; DENERVATION; DIABETES MELLITUS; DISEASE SEVERITY; HUMAN; HYPERTENSION; VASCULAR AMYLOIDOSIS; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; WHITE MATTER;

EID: 0033391684     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1999.tb07821.x     Document Type: Conference Paper

References (75)

1. 1. Alzheimer, A. 1907. Uber eine eigenartig Erkrankung der Hirnrinde. Allg. Z. Psychiatrie Psych. Ger. Med. 64: 146-148.
2. 2. Kalaria, R.N. 1996. Cerebral vessels in ageing and Alzheimer's disease. Pharm. Therap. 72: 193-214.
3. 3. Vinters, H.V. 1987. Cerebral amyloid angiopathy: a critical review. Stroke 18: 311-324.
4. 4. Heyman, A. et al. 1998. Cerebral infarcts in patients with autopsy-proven Alzheimer's disease. CERAD Part XVIII. Neurology 51: 159-162.
5. 5. Premkumar, D.R.D. et al. 1996. Apolipoprotein E ε4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology in Alzheimer's disease. Am. J Pathol. 148: 2083-2095.
6. 6. Hachinski, V. & D. Munoz. 1997. Cerebrovascular pathology in Alzheimer's disease: cause, effect or epiphenomeneon. Ann. N.Y. Acad. Sci. 826: 1-6.
7. 7. Pasquier, F. et al. 1998. The influence of coincidental vascular pathology on symptomatology and course of Alzheimer's disease. J. Neural Transm. Suppl. 54: 117-127.
8. 8. Kalaria, R.N. & Harik, S.I. 1989. Reduced glucose transporter at the blood-brain barrier and cerebral cortex in Alzheimer's disease. J. Neurochem. 53: 1083-1088.
9. 9. Frey, K.A. 1998. Neurochemical imaging of Alzheimer's disease and other degenerative dementias. Q. J. Nucl. Med. 42: 166-178.
10. 10. Mielke, R. & W.D. Heiss. 1998. Positron emission tomography for diagnosis of Alzheimer's disease and vascular dementia. J. Neural Transm. Suppl. 53: 237-250.
11. 11. Kalaria, R.N. & P. Hedera. 1995. Differential degeneration of the endothelium and basement membrane of capillaries in Alzheimer's disease. Neuroreport 6: 477-480.
12. 12. Kawai, M. et al. 1990. The relationship of amyloid plaques to cerebral capillaries in Alzheimer's disease. Am. J. Pathol. 37: 1435-1446.
13. 13. Kalaria, R.N. 1992. The blood-brain barrier and cerebral microcirculation in Alzheimer's disease. Cerebrovascular Brain Metab. 4: 226-260.
14. 14. Jagust, W.J. et al. 1991. Diminished glucose transport in Alzheimer's disease. Cereb. Blood Flow Metab. 11: 323-330.
15. 15. Marcus, D.L. & M.L. Freedman. 1997. Decreased brain glucose metabolism in microvessels from patients with Alzheimer's disease. Ann. N.Y. Acad. Sci. 826: 248-253.
16. 16. Stewart, P.A. et al. 1992. A mophometric study of the blood brain barrier in Alzheimer's disease. Lab. Invest. 67: 734-742.
17. 17. Akiyama, H. et al. 1993. Expression of intercellular adhesion moleculae (ICAM)-1 by a subset of astrocytes in Alzheimer disease and some other degenerative neurological disorders. Acta Neuropathol. 85: 628-634.
18. 18. Frohman, E.M. 1991. Expression of intercellular adhesion molecule (ICAM-1) in Alzheimer's disease. J. Neurol. Sci. 106: 105-111.
19. 19. Verbeek, M.M. et al. 1994. Accumulation of intercellular adhesion molecule-1 in senile plaques in brain tissue of patients with Alzheimer's disease. Am. J. Pathol. 144: 104-116.
20. 20. Kalaria, R.N. 1993. The immunopathology of Alzheimer's disease. Brain Pathol. 3: 333-347.
21. 21. Lerner, A. et al. 1993. Cell adhesion molecules in the vascular and neocortical pathology of Alzheimer's disease. Soc. Neurosci. Abstr. 19: 623.
22. 22. Wisniewski, H.M. & P.B. Kozlowski. 1982. Evidence for bloodbrain barrier changes in senile dementia of the Alzheimer type (SDAT). Ann. N. Y. Acad. Sci. 396: 119-131.
23. 23. Munoz, D.G. et al. 1997. Serum protein leakage in Alzheimer's disease revisited. Ann. N. Y. Acad. Sci. 826: 173-189.
24. 24. Kalaria, R.N. et al. 1991. Serum amyloid P in Alzheimer's disease. Implications for dysfunction of the blood-brain barrier. Ann. N. Y. Acad. Sci. 640: 145-148.
25. 25. Hardy, J. et al. 1986. An integrative hypothesis concerning the pathogenesis and progression of Alzheimer's disease. Neurobiol. Aging 7: 489-502.
26. 26. Perlmutter, L.S. et al. 1994. Vascular basement membrane components and the lesions of Alzheimer's disease: Light and electron microscopic analyses. Microscopy Res. Tech. 28: 204-215.
27. 27. Blennow, K. et al. 1990. Blood-brain barrier disturbance in patients with Alzheimer's disease is related to vascular factors. Acta Neurol. Scand. 81: 349-351.
28. 28. Hampel, H. et al. 1995. Evidence of blood-cerebrospinal fluid-barrier impairment in a subgroup of patients with dementia of the Alzheimer type and major depression: a possible indicator for immunoactivation. Dementia 6: 348-354.
29. 29. Kay, A. et al. 1987. CSF and serum concentration of albumin and IgG in Alzheimer's disease. Neurobiol. Aging 8: 2125.
30. 30. Mecocci, P. et al. 1991. Blood.brain barrier in a geriatric population: barrier function in degenerative and vascular dementia. Acta Neurol. Scand. 84: 210-213.
31. 31. Skoog, I. ef al. 1998. A population-study on blood-brain barrier function in 85-year-olds. Relation to Alzheimer's disease and vascular dementia. Neurology 50: 966-971.
32. 32. Kawai, M. et al. 1993. Degeneration of amyloid precursor protein-containing smooth muscle cells in cerebral amyloid angiopathy. Brain Res. 623: 142-146.
33. 33. Perry, G. et al. 1998. Cerebrovascular muscle atrophy is a feature of Alzheimer's disease. Brain Res . 791: 63-66.
34. 34. Miyakawa, T. 1997. Electron microscopy of amyloid fibrils and microvessels. Ann. N. Y. Acad. Sci. 826: 25-34.
35. 35. Kalaria, R.N. & A.B. Pax. 1995. Increased collagen content of cerebral microvessels in Alzheimer's disease. Brain Res. 705: 349-352.
36. 36. Scheibel, A.B. et al. 1987. Denervation microangiopathy in senile dementia, Alzheimer type. Alz. Dis. Assoc. Dis. 1: 19-37.
37. 37. Claudio, L. 1996. Utrastructural features of the blood-brain barrier in biopsy tissue from Alzheimer's disease patients. Acta Neuropathol. 91:6-14.
38. 38. Kalaria, R.N. et al. 1998. Vascular endothelial growth factor in Alzheimer's disease and experimental cerebral ischemia. Mol. Brain Res. 62: 101-105.
39. 39. Kalaria, R.N. et al. 1996. Production and increased detection of amyloid β-protein and amyloidogenic fragments in brain microvessels, meningeal vessels and choroid plexus in Alzheimer disease. Mol. Brain Res. 35: 58-68.
40. 40. Gray, F. 1994. Creutzfeldt-Jakob disease and cerebral amyloid angiopathy. Acta Neuropathol. 88: 106-111.
41. 41. De La Torre, J.C. 1997. Hemodynamic consequences of deformed microvessels in the brain in Alzheimer's disease. Ann. N. Y. Acad. Sci. 826: 75-91.
42. 42. Weller, R.O. et al. 1998. Cerebral amyloid angiopathy: amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease. Am. J. Pathol. 153: 725-733.
43. 43. De Jong, G.I et al. 1997. Cerebrovascular hypoperfusion: a risk factor for Alzheimer's disease? Ann. N. Y. Acad. Sci. 826: 56-74.
44. 44. Olichney, J.M. et al. 1995. Cerebral infarction in Alzheimer's disease is associated with severe amyloid angiopathy and hypertension. Arch. Neurol. 52: 702-708.
45. 45. Haan, J. et al. 1990. Dementia in hereditary cerebral hemorrhage with amyloidosis-Dutch type. Arch. Neurol. 47: 965-968.
46. 46. Wilson, P.W.F. et al. 1994. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease: the Framingham offspring study. JAMA 272: 1666-1671.
47. 47. Davignon, J. et al. 1988. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 8: 1-21.
48. 48. Kalaria, R.N. & D.R.D. Premkumar. 1995. Apolipoprotein E genotype and cerebral amyloid angiopathy in Alzheimer's disease. Lancet 346:1424.
49. 49. Greenberg, S.M. et al. 1995. Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy. Ann. Neurol. 38: 254-259.
50. 50. Nicoll, J.A. et al. 1997. High frequency of apolipoprotein epsilon 2 allele in hemorrhage due to cerebral amyloid angiopathy. Ann. Neurol. 41: 716-721.
51. 51. Olichney, J.M. et al. 1996. Apolipoprotein epsilon 4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer's disease and Lewy body variant. Neurology 47: 190-196.
52. 52. Zarow, C. et al. 1999. Cerebral amyloid angiopathy in Alzheimer's disease is associated with apolipoprotein E4 and cortical neuron loss. Alz. Dis. Assoc. Dis. 13: 1-8.
53. 53. Greenberg, S.M. et al. 1998. Association of apolipoprotein E epsilon 2 and vasculopathy in cerebral amyloid angiopathy. Neurology 50: 961-965.
54. 54. McCarron, M.O. & J.A. Nicoll. 1998. High frequency of apolipoprotein E epsilon 2 allele is specific for patients with cerebral amyloid angiopathy-related haemorrhage. Neurosci. Lett. 247: 45-48.
55. 55. Margaglione, M. et al. 1998. Prevalence of apolipoprotein E alleles in healthy subjects and survivors of ischemic stroke: an Italian Case-Control Study. Stroke 29: 399-403.
56. 56. Frisoni, G.B. et al. 1994. Apolipoprotein E ε4 allele in Alzheimer's disease and vascular dementia. Dementia 5: 240-242.
57. 57. Bronge, L. et al. 1999. White matter lesions in Alzheimer patients are influenced by apolipoprotein E genotype. Dement. Geriatr. Cogn. Disord. 10: 89-96.
58. 58. Hofman, A. et al. 1997. Atherosclerosis, apolipoprotein E, and the prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 349: 151-154.
59. 59. Kalaria, R.N. 1997. Apolipoprotein E, arteriosclerosis and Alzheimer's disease. Lancet 349: 1174-1175.
60. 60. Kosunen, O. et al. 1995. Relation of coronary atherosclerosis and apolipoprotein E genotypes in Alzheimer patients. Stroke 26: 743-748.
61. 61. Skoog, I. et al. 1997. Apolipoprotein E in cerebrospinal fluid in 85-year-olds. Relation to dementia, apolipoprotein E polymorphism, cerebral atrophy, and white-matter lesions. Arch. Neurol. 54:267-272.
62. 62. Skoog, I. et al. 1998b. A population study of Apo E genotype at the age of 85: relation to dementia, cerebrovascular disease and mortality. J. Neurol. Neurosur. Psychiatr. 64: 37-43.
63. 63. Notkola, I-L. et al. 1998. Serum total cholesterol, apolipoprotein E ε4 allele, and Alzheimer's disease. Neuroepidemiology 17: 14-20.
64. 64. Wallin, A. 1998. The overlap between Alzheimer's disease and vascular dementia: the role of white matter changes. Dement. Geriatr. Cogn. Disord. 9(Suppl. 1): 30-35.
65. 65. Englund, E. 1998. Neuropathology of white matter changes in Alzheimer's disease and vascular dementia. Dement. Geriatr. Cogn. Disord. 9(Suppl. 1): 6-12.
66. 66. Scheltens, P. et al. 1992. White matter lesions on magnetic resonance imaging in clinically diagnosed Alzheimer's disease. Evidence for a heterogeneity. Brain 115: 735-748.
67. 67. Barber, R. et al. 1999. White matter lesions on magnetic resonance imaging in dementia with lewy bodies, Alzheimer's disease, vascular dementia, and normal aging. J. Neurol. Neurosurg. Psychiatry 67: 66-72.
68. 68. Van Gijn, G. 1998. Leukoariosis and vascular dementia. Neurology 51(Suppl. 3): S3-S8.
69. 69. Wahlund, L.O. et al. 1994. White matter hyperintensities in dementia: does it matter? Magn. Reson. Imaging 12: 387-394.
70. 70. Leys, D. et al. 1991. Could Wallerian degeneration contribute to "leuko-araiosis" in subjects free of any vascular disorder? J. Neurol. Neurosurg. Psychiatr. 54: 46-50.
71. 71. De La Monte, S.M. 1989. Quantitation of cerebral atrophy in preclinical and end-stage Alzheimer's disease. Ann. Neurol. 25: 450-459.
72. 72. Skoog, I. 1997. The relationship between blood pressure and dementia: a review. Biomed. Pharmacother. 51: 367-375.
73. 73. Sparks, D.L. et al. 1990. Cortical senile plaques in coronary artery disease, aging and Alzheimer's disease. Neurobiol. Aging 11: 601-607.
74. 74. Henon, H. et al. 1997. Pre-existing stroke in patients: baseline frequency, associated factors and outcome. Stroke 28: 2429-2436.
75. 75. Kokmen, E. et al. 1996. Dementia after ischaemic stroke: a population based study in Rochester, Minnesota (1960-1984). Neurology 46: 154-159.